The number of biopharma and biotech companies developing and launching new therapies is continuing to rise with emerging biopharma remaining a strong source of innovation. At the same time, more barriers to success are emerging with requirements for increasingly complex clinical trials, continuous regulatory changes, evolving payer conditions, and more restrictive access to HCPs. It’s..

The number of biopharma and biotech companies developing and launching new therapies is continuing to rise with emerging biopharma remaining a strong source of innovation. At the same time, more barriers to success are emerging with requirements for increasingly complex clinical trials, continuous regulatory changes, evolving payer conditions, and more restrictive access to HCPs. It’s..

The number of biopharma and biotech companies developing and launching new therapies is continuing to rise with emerging biopharma remaining a strong source of innovation. At the same time, more barriers to success are emerging with requirements for increasingly complex clinical trials, continuous regulatory changes, evolving payer conditions, and more restrictive access to HCPs. It’s..

Location: Dana Point, CA   Convening more than 500 of the world’s leading clinicians, industry executives, investors, patient advocates, payers, policy experts, and researchers, the 16th Annual Personalized Medicine Conference will facilitate a cross-sector exchange of perspectives on the scientific, business, and policy issues influencing the status and outlook for personalized medicine in the wake of a..

The number of biopharma and biotech companies developing and launching new therapies is continuing to rise with emerging biopharma remaining a strong source of innovation. At the same time, more barriers to success are emerging with requirements for increasingly complex clinical trials, continuous regulatory changes, evolving payer conditions, and more restrictive access to HCPs. It’s..

Location: Virtual   The Fierce Leaders in Life Sciences Forum brings together forward-thinking minds from today’s life sciences industry and features insights from C-suite and executive leadership on the end-to-end drug development process, highlighting innovative approaches in today’s evolving healthcare landscape to conducting: R&D and translational science Clinical development Product commercialization Top Reasons to Attend Industry Updates: Hear from..